Comparison of Paliperidone Palmitate from Different Crystallization Processes and Effect on Formulations In Vitro and In Vivo

Abstract

The quality of active pharmaceutical ingredients (APIs) is an important factor which can affect the safety and efficacy of pharmaceuticals. This study was designed to investigate the nature of paliperidone palmitate (PP) obtained by different crystallization processes, then compare the characteristics between test formulations which prepared PP of different crystallization and reference formulations (Invega Sustenna®) in vitro and in vivo. Two different PPs, namely PP-1 and PP-2, were prepared by different crystallization methods. Contact angle, morphology, and crystallinity of the PPs were characterized. Taking the particle sizes and distribution of Invega Sustenna® as reference, test formulations were prepared by the wet milling method using either a PP-1 or PP-2 sample. Their release behavior, stability in vitro, and pharmacokinetics in vivo were subsequently investigated. The results indicated that PP-2 had a higher surface free energy (SFE). More small particles were attached to the PP-1 surface under the influence of crystallization temperature. Different crystallization processes did not change the crystal of PP, but changed the crystallinity of PP. There was no obvious difference in in vitro releases between test formulations. However, the stability and state of formulation containing PP-2 were better compared to formulations containing PP-1, indicated by differences in crystallinity and SFE. Meanwhile, pharmacokinetic in vivo results demonstrated that the pharmacokinetic profiles and parameters of formulation containing PP-2 and Invega Sustenna® tended to be consistent, but those of formulations containing PP-1 were significantly different from those of formulations containing PP-2 or Invega Sustenna®, and there was burst release phenomenon of formulations containing PP-1 in rats. PP made by different crystallization processes could induce changes in appearance, SFE, and crystallinity, and further affect the stability, state, and pharmacokinetic in vivo formulation.

Pharmaceutical Factors Affecting Bioavailability and Bioequivalency: Physical and Chemical Properties of the Active Substance, Traditional Review

“…İn vitro çalışmalar fizyolojik pH'lerde (pH 1,2, 4,5 ve 6,8) in vitro çözünme profillerinin benzerliğinin ortaya konulması ile yapıl-maktadır. 2,3 Klinik çalışmalar ise sağlıklı gönüllülerde (bazı durumlarda gönüllü hastalarda) açlık koşullarında, kanda veya idrarda birincil parametreler olan plazma derişimi-zaman eğrisi altında kalan alan, maksimum plazma derişimi ve maksimum plazma derişimine ulaşma zamanı belirlenerek, bu değerlerin logaritmik dönüştürme sonrası istatistiksel olarak %90 güven aralığında %80-125 sınırları arasında kalması durumu değerlendirilerek yapılmaktadır. 4,5 Farmasötik dozaj şeklinden bir ilacın biyoyararlanımını etkileyen faktörler, etkin maddeye ait fizikokimyasal özellikler, dozaj şekline ait özellikler ve ilaç uygulama bölgesine ait anatomik ve fizyolojik özellikler olarak sıralanabilir.…”